Ceribell CTO sells EUR 102,207 after Q2 growth and a cluster of executive sales

Ceribell’s Raymond Woo did not dump stock into a vacuum. He sold on September 8, the company had just come off a strong second quarter, and the shares were still hovering near recent highs when they closed at $23.43 on September 10. That is the timeline that matters here, because the filing lands after a revenue print that gave the story real momentum and before the market had fully decided how much of that momentum to keep.

The broader tape was not especially forgiving either. The S&P 500 and Nasdaq Composite both finished lower on September 10, while medtech has spent much of 2026 lagging broader indices on tariff noise and uneven hospital volumes. Ceribell sits in the part of healthcare where growth still gets rewarded, but only if the market believes the growth can keep compounding. That is the backdrop for a sale by the chief technology officer, not a footnote.

The June 5 plan, the September 8 sale, and why the date matters

Woo’s sale was pre-arranged. The filing says the Rule 10b5-1 trading plan was adopted on June 5, 2026, and the September 8 transaction followed that plan. He sold 4,887 shares at $24.33 per share, for roughly $119,000 in gross proceeds, which the ingest normalised to about EUR 102,207. That is the cleanest fact pattern in the filing, and it matters because it narrows the room for storytelling. This was not a surprise discretionary exit. It was a scheduled sale executed after a plan was put in place months earlier.

Still, scheduled does not mean irrelevant. Ceribell’s market value sits around EUR 783.9 million in the dossier, so EUR 102,207 is not a balance-sheet event. But our scoring leans on exactly this kind of thing, an operating director filing in a small or mid-cap name, inside a cluster, at a size that is roughly 0.01% of market value. That is the sort of trade that can matter more than the dollar amount suggests, especially when the company is still early in its commercial run and the stock has already had a strong year.

The date sequence also matters because the sale came after the company’s second quarter numbers changed the narrative. Ceribell reported revenue of $28.1 million in Q2 2026, up 33% year over year, and raised full-year revenue guidance to $114 million to $117 million. Gross margin reached a record 92%, or 89% excluding tariff refunds. Those are the numbers the market was digesting before the filing hit, and they are the numbers that make any insider sale feel more worth parsing than usual.

Ceribell’s second quarter changed the conversation

Ceribell develops AI-powered point-of-care EEG systems for rapid seizure detection and monitoring in acute-care settings. That is a narrow niche, but it is a real one, and the company has been building into it with more indications and more hospital penetration. The platform has expanded through FDA clearances into neonatal and pediatric use and delirium monitoring, and CMS New Technology Add-on Payment support of up to $2,171 per eligible Medicare case is set to begin on October 1, 2026. That reimbursement detail is not a side note. In this market, reimbursement can turn a useful device into a budgetable one.

The second quarter print gave the stock something more durable than a one-off headline. Revenue growth at 33% year over year is not the kind of number you get from a mature medtech name coasting on installed base. It points to utilization, adoption, and a sales motion that is still finding room to run. The company also said systems are deployed in over 680 U.S. hospitals, which tells you the commercial footprint is real but still early relative to the size of the acute-care market it is trying to address.

Analysts have stayed constructive off that print. BTIG raised its target to $30 from $28 and kept a Buy rating, Canaccord moved to $26 from $25 and also stayed positive, and Raymond James reiterated Buy with a $29 target. Consensus coverage leans Strong Buy with an average target near $28. That does not make the stock cheap, and it does not make the path straight. It does tell you the sell-side has been willing to underwrite the growth story after the quarter, which is part of why a CTO sale now reads differently than it would have six months ago.

Why the cluster matters here

InsiderTrades data flags Ceribell as a cluster name, and the recent declarations show why. The dossier lists 12 recent declarations and three distinct insiders, with activity from Woo and CFO David Foehr in the same window. MarketBeat’s insider-trade page also shows broader selling by the CEO, CFO, and other executives in recent months, often tied to option exercises or scheduled plans. That is the pattern here, repeated sales rather than a single isolated print.

The cluster matters because it changes the burden of proof. One scheduled sale by one executive can be written off as routine compensation management. Multiple sales across senior roles, even when some are tied to exercises or plans, tell you the company is in a period where insiders are monetising equity after a strong move. That is not a verdict on the business. It is a reminder that the stock has already done a lot of work for them.

InsiderTrades data also places the name in a bucket that has historically been useful for context, not prophecy. The relevant cohort, director-level buys at sweet-spot names between EUR 300 million and EUR 1 billion in market value, has a 53% 90-day win rate and a 3.99% average 90-day return across 6,007 observations. That is historical cohort data, not a forecast for Ceribell, and it is not a promise that this filing leads to anything in particular. It does, however, explain why our framework pays attention to operating-level filings in this size band. The market has often been slower to fully price them.

What the stock has already priced, and what it has not

Ceribell closed at $23.43 on September 10, down about 4% on the session, after trading near recent highs above $24 to $25. The stock has also delivered strong year-to-date gains from lower levels, more than 100% according to the grounded research. That matters because insider selling looks different after a stock has already doubled than it does after a long drawdown. A sale into strength is not the same as a sale into weakness, and the market knows the difference.

The medtech backdrop is mixed. PitchBook’s sector note says the group has lagged broader indices in 2026, with tariff uncertainty and hospital volume trends weighing on sentiment. That is a useful counterweight to the Ceribell story. The company is not being lifted by a broad sector rerating. It is trying to earn its own multiple through growth, reimbursement, and product expansion. If the market decides the second quarter was a one-quarter burst rather than the start of a longer utilization curve, the stock can reprice quickly.

The company’s own commercial footprint gives bulls something to point to. Ceribell has expanded into neonatal and pediatric seizure detection, and into delirium monitoring, which broadens the use case beyond the original rapid EEG niche. The CMS NTAP support effective October 1 adds another layer. But the stock already reflects a good deal of that optimism, and the insider cluster says senior management has been willing to sell into the move. That is the tension in the name now.

Comparable names are thinner than the story makes them sound

Direct public comparables are limited, which is part of why Ceribell can trade on its own narrative for longer than a more crowded medtech category. Zeto is still focused on wireless portable EEG headsets for outpatient, ICU, and home settings, and Epitel raised $26 million in July 2026 to advance a wearable remote EEG system. Those are useful reference points, but they are not the same public-market test case. Natus Medical is a larger traditional EEG player, and Ceribell has even faced patent litigation from it, but that is more a sign of competitive friction than a clean valuation peer.

The better comparison set is probably not pure EEG at all. Names like iRhythm trade on different multiples and different growth profiles, but they show how investors value monitoring businesses when recurring use, workflow integration, and reimbursement line up. Ceribell is trying to build that kind of habit in acute care, where the underuse of traditional EEG has left room for a faster bedside system. If the company keeps converting hospitals into repeat users, the market can keep paying for growth. If utilization stalls, the premium will not last long.

That is why the insider sale should be read against the operating print, not against a generic medtech chart. The company is still in a phase where each quarter can change the market’s estimate of the runway. The CTO’s sale does not tell you the runway is gone. It does tell you some of the people inside the story have already taken chips off the table after the stock’s run and the quarter’s upside.

What to watch after the filing

The next real test is not the filing itself. It is whether Ceribell can keep turning hospital deployments into usage, and usage into revenue, while the reimbursement backdrop improves rather than disappoints. The October 1 NTAP timing is one marker. The next earnings update is another. If the company can show that Q2 was not a one-off acceleration, the market will probably keep giving it room despite the insider sales.

Watch the mix of future filings as well. A lone 10b5-1 sale is one thing. More selling from the CEO or CFO, especially if it comes after the stock has held its gains, would keep the cluster conversation alive. On the other side, a pause in selling after the recent wave would make the current activity look more like a monetisation window than a broader change in tone. You do not need to overread every Form 4. You do need to notice when the same names keep appearing.

InsiderTrades strategy data is only a framework, and the live out-of-sample headline remains a placeholder token, 0.81, 26.4, and 51.5, on a restricted EU venue universe with a short, single-regime window. That is useful as a screen, not as a promise. For Ceribell, the more immediate question is simpler. Can a company that just posted 33% revenue growth, record gross margin, and a raised guide keep compounding fast enough that a CTO sale on September 8 looks like routine monetisation rather than the first sign of fatigue?

September 8 was scheduled, but the market still has to price it

The filing itself is plain enough. Woo sold under a plan adopted on June 5, at $24.33, after option exercises, and the euro-normalised value came to about EUR 102,207. The market does not have to make more of that than the facts allow. But it also does not have to ignore the timing, because the timing sits right on top of a quarter that changed the tone around Ceribell.

The question now is whether the stock can absorb a scheduled sale, a raised guide, and a visible insider cluster without losing the market’s attention.

Dig deeper: Ceribell, Inc.'s full insider filing history.

This is not investment advice.